SynthesisUpdates in surgery2026
Rigid-platform transanal excision (TEM/TEO/TAMIS) for rectal neuroendocrine tumours: a single-centre TEM/TEO series and systematic review.
Synthesis in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rectal neuroendocrine tumours (rNETs) are increasingly detected and often amenable to organ-preserving local therapy. Rigid transanal platforms (TEM/TEO/TAMIS) offer en bloc, full-thickness excision with precise margin control; however, contemporary evidence is limited. We report our single-centre outcomes and contextualise them with a focused, PRISMA-guided systematic review. We retrospectively analysed a prospectively maintained database of consecutive rNETs treated with TEM/TEO (1993–2025). The primary endpoint was R0 resection; secondary endpoints included complications, length of stay, residual tumour at completion excision, and oncologic outcomes. In parallel, we systematically searched PubMed/MEDLINE and Embase (last update August 1st 2025) for studies reporting outcomes of rigid transanal excision for rNETs (TEM/TEO/TAMIS/robotic TAMIS). Purely endoscopic series, radical resections, and case reports (< 5 patients) were excluded. Fourteen patients underwent local excision (median age 64 years; median distance from anal verge 7.5 cm). Tumour size was captured using two complementary metrics: preoperative endoscopic diameter (diameter pre) and histological diameter on the resected specimen (diameter histo), both reported in millimetres (mm). Median diameter pre was 20 mm (IQR 20–30; range 20–100), while median diameter histo was 30 mm (IQR 20–30; range 10–60). Histology revealed 10 G1 and 4 G2 tumours; lymphovascular invasion was present in 2 (14.3%). All procedures were completed transanally; the median operative time was 52 min, and the median stay was 2 days. One minor complication (Clavien–Dindo II) occurred. R0 resection was achieved in 14/14 (100%); among five completion excisions, residual tumour was present in 2 (40%). Over a median follow-up of 36 months (IQR 26–48; range 12–72), one patient (7.1%) recurred (nodal) and underwent salvage total mesorectal excision. The systematic review included 11 studies (~ 440 unique patients). Across series, R0 rates were typically 96–100%, morbidity was low (< 10%, mostly minor), and residual tumour at completion occurred in ~ 20–40% after incomplete endoscopic resection. Recurrences were uncommon but could occur late (> 10 years). Rigid transanal excision achieves high-quality local control with low morbidity and provides reliable full-thickness clearance after incomplete endoscopic resection. The combined presentation of our institutional series with a focused review clarifies where TEM/TEO/TAMIS most benefits rNET care—particularly for completion surgery and intermediate-risk lesions—within contemporary guideline frameworks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.